An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
about
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animalsRole of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationDipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular DiseaseExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsGlucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.Adipose tissue dysfunction as a central mechanism leading to dysmetabolic obesity triggered by chronic exposure to p,p'-DDE.Treatment of diabetic kidney disease: current and future targets.The nonglycemic actions of dipeptidyl peptidase-4 inhibitorsPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemCardiovascular impact of drugs used in the treatment of diabetesDPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes.Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null miceThe pathophysiology of hypertension in patients with obesity.Targeting metabolic disturbance in the diabetic heart.A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice.Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts.DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes.Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease.Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.Inter-tissue coexpression network analysis reveals DPP4 as an important gene in heart to blood communication.Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells.Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes.Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.CD8+ T Cells and Macrophages Regulate Pathogenesis in a Mouse Model of Middle East Respiratory Syndrome.Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidenceEctoenzymes in leukocyte migration and their therapeutic potential.Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.Moonlighting adenosine deaminase: a target protein for drug development.Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.An updated review on cancer risk associated with incretin mimetics and enhancers.DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation.
P2860
Q26749176-92C5D034-6B99-437F-8F15-EB344C0E3E7DQ26778329-47792AB6-7F42-4656-8E22-3803EE13C7CBQ26781269-A246BBEA-EEDB-4813-B048-6B4D6876D07CQ26801173-C4E42DD6-8300-4A46-B3C4-6DD49365922CQ28081569-9C54BF62-B8FE-414A-A2CD-52D43F50D64BQ33434017-EE5CD164-048E-455F-BC84-A4BF576D8ADAQ33752824-1F19A371-7D00-483B-AF61-B6EE9E01159FQ33907249-0138FF40-62DD-4B1B-AAE9-193C402B1C96Q34029715-9B8D2B03-A112-442B-979A-F958A433A8CEQ34062829-42DDE3F0-FD87-4114-8325-42DC2F338DDCQ34383575-ADF6564F-0169-4E98-AD1A-8EADF1F911C5Q34566411-03224115-C3EA-41B0-9A8B-B2ACB5774283Q34963221-0767DAAD-D593-4FEE-BCEE-2D456F4DA362Q35021492-A7CB4F48-D260-4232-A804-43D7FDD4E8BBQ35084845-94F7BB6F-4F9D-4785-B7A4-03FF1594EDD0Q35175774-6EBE538E-7179-4CD8-9613-5EE8A6F91085Q35531314-91F5A3AA-4DF5-49F4-9739-08E591DC7C33Q35690114-4FD74083-2DAD-4C47-B7EA-739C25F0C400Q36064392-7D0EBC8E-DA92-4969-BB22-26A0AD51BE9EQ36139664-DEE1C2C9-7508-499A-8450-CDAB4E8DCE7DQ36448319-C632995E-F35D-4242-85AA-DD0D6EAA3464Q36560920-C97889EA-73DA-424C-9EBD-6BD7CF65375EQ36568187-2A25659C-2E5F-42DC-9CA5-D99ED4903FF1Q36687153-51366996-F430-4396-8890-44B1A64D05D2Q36694480-F00F461C-B1FE-422B-A5C6-27E51F299ABEQ36964223-0CDC38D9-FAAE-4515-89D3-ECE1687E8141Q37366826-6B9FBF05-B17B-41F3-A7D5-5005F7211166Q37512816-DE0D89FA-D88F-4A51-92F0-4A99EF393E46Q37699068-ED162BC3-6D35-426D-82E6-DD8B800C3673Q38121545-5C94AFDF-B304-4B01-AECD-D02526A9FC61Q38196724-2B0D0718-3612-47F2-9AA3-E88CE2026F49Q38212472-F2CE1A16-7155-4630-99D8-19E6F49DFF33Q38220597-67F5DCAD-DD1B-46DF-9A43-507DA2942569Q38222628-FFF874D3-ED14-4A7C-91A4-0C0E3019D4D1Q38371242-0AC10D8C-E3AC-45E2-859D-602AC32D042FQ38388920-7E5E3FE7-9295-422C-B96B-090978E42188Q38413395-FF6BAAF6-8454-45F9-8134-8CA7C3B8CFDAQ38546981-AEE938AC-72E3-44FF-B22A-0C770E03C89CQ38556037-928396BF-6C75-40B8-A56C-DDAF5366CA84Q38747179-D78C71A8-7B1B-4E12-B09B-D8DB515443E9
P2860
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
An emerging role of dipeptidyl ...... ons in cardiovascular disease.
@en
type
label
An emerging role of dipeptidyl ...... ons in cardiovascular disease.
@en
prefLabel
An emerging role of dipeptidyl ...... ons in cardiovascular disease.
@en
P2093
P1433
P1476
An emerging role of dipeptidyl ...... ons in cardiovascular disease.
@en
P2093
Jixin Zhong
Sanjay Rajagopalan
Xiaoquan Rao
P304
P356
10.1016/J.ATHEROSCLEROSIS.2012.09.012
P577
2012-09-21T00:00:00Z